ADOCIA Reports Fourth Quarter 2025 Financial Results and Provides a Business Update

February 24, 2026 - 19:13

LYON, France, February 24, 2026 -- Adocia, a clinical-stage biopharmaceutical company, has announced its financial results for the fourth quarter ending December 31, 2025, alongside a comprehensive update on its corporate progress. The company remains dedicated to advancing its pipeline of innovative therapies targeting diabetes and obesity.

During the quarter, the company highlighted significant advancements across its key clinical assets. Notably, the Phase 3 clinical trial for its lead insulin candidate continues to progress as planned, with patient enrollment on track. Management emphasized the program's strategic importance in addressing substantial unmet needs within the diabetes care landscape. Furthermore, the company reported positive momentum in its earlier-stage research initiatives, particularly in developing novel combinations for metabolic diseases.

Financially, the quarter reflected a period of strategic investment aligned with these clinical milestones. The reported cash position is stated to be sufficient to fund planned operations and key development objectives into the upcoming period. This financial runway is deemed critical for advancing the portfolio through upcoming clinical readouts and regulatory interactions.

Company leadership expressed confidence in the direction of its research programs, underscoring a commitment to delivering long-term value by addressing complex challenges in endocrinology. The focus remains on executing the clinical development strategy and moving closer to bringing new therapeutic options to patients worldwide.